Navigation Links
BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
Date:8/5/2013

al of skin lesions has completed a Phase 1/2 study; BL-7040 for treating inflammatory bowel disease (IBD) has completed a Phase 2a trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has commenced a Phase 2 study; BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study; BL-1021 for neuropathic pain is in Phase 1 development; and BL-1020 for schizophrenia. In addition, BioLineRx has five products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase 3) and commercialization. For more information on BioLineRx, please visit www.biolinerx.com, the content of which does not form a part of this press release.

Various statements in this release concerning BioLineRx's future expectations, including specifically those related to the development and commercialization of BL-8040, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking stateme
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Nurtur Health, Inc. (Nurtur), a wholly owned subsidiary ... honored by Dorland Health,s Case in Point ... to Peach State Health Plan,s teenage members with asthma. ... Platinum Awards recognize population health management programs that successfully ... and settings in the continuum of care coordination. Nurtur ...
(Date:5/27/2015)... May 27, 2015   AMC Health , a ... that it has successfully undergone a third-party review of ... 21 CFR 820 and 21 CFR 11 for its ... the first of its kind for clinical trials. ... of quality assurance/regulatory compliance and business operations in the ...
(Date:5/27/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) and ... Roche Group, announced today a global agreement to collaborate ... commercialize, a companion diagnostic assay for use with Halozyme,s ... assay will be used to identify high levels of ... natural sugars distributed throughout human tissue – that can ...
Breaking Medicine Technology:Nurtur's Asthma Management Program Wins Award from Dorland Health 2AMC Health Quality Management System for Telehealth in Clinical Trials Use Compliant with 21 CFR 820 and 21 CFR 11 Requirements 2Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 2Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 3Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 4Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For Cancer Treatment 5
(Date:5/27/2015)... Tx (PRWEB) May 27, 2015 ... germline pharmacogenomic and somatic genomic analysis in personalized cancer ... published by the American Society of Clinical Oncology (ASCO) ... June 2 in Chicago. , The molecular and clinical ... Cancer Genome Atlas (TCGA) database. The study reports improved ...
(Date:5/27/2015)... Ohio (PRWEB) May 27, 2015 Cincinnati Veterans ... & Research for Veterans (CERV) Foundation is proud to host ... fair for women Veterans June 11 at the Freedom Center ... Karin Johnson will be the emcee. , This event ... devotion to the nation. The banquet is free to ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 ... of its SonarMD Platform, a first-of-its kind, ... and managing patients with chronic gastrointestinal disease. ... MD, MBA, the application allows physicians to ... through the ongoing use of electronic health ...
(Date:5/27/2015)... May 27, 2015 With a prevalently ... poll conducted during the "ACA - Controlling the Chaos" ... 75% are currently in the process of researching ... were confidently prepared for the reporting mandates. , According ... the webinar, those who are currently vetting ACA reporting ...
(Date:5/27/2015)... 2015 A television program using health ... and Roswell Park Cancer Institute winning a ... story, Cancer Can’t Win , highlights the amazing ... Institute. The production team followed five people who were ... they received treatment from doctors and medical experts at ...
Breaking Medicine News(10 mins):Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2Health News:Employers are On Track for ACA Reporting According to Businessolver Poll 2Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 2Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 3
... Jewish Health has received a grant for $950,308 from ... San Luis Valley with educational materials for patients and ... the most common chronic illness in children and adults, ... The San Luis Valley has one of the highest ...
... his State of the State announcement of a tenfold ... Kasich joined medical researchers from across the state on ... the faster network speeds will help enhance innovation. ... Medical Center, Case Western Reserve University School of Medicine, ...
... Mann HealthDay Reporter , MONDAY, Feb. 27 (HealthDay ... much needed rest at night, but using them routinely might ... develop certain types of cancer, research suggests. A new ... times more likely to die than people who don,t take ...
... is studying the differences between the social impairments found ... for people with both disorders. Autism spectrum disorder ... but they share similarities in social dysfunction. For many ... young people with ASD were thought to have a ...
... heart disease may not be able to compensate for their ... to Penn State researchers, making snow shoveling and other activities ... why cold air is such a trigger for coronary events," ... of the Heart and Vascular Institute, Penn State College of ...
... EAST LANSING, Mich. Often faced with overwhelming anxiety, patients ... and new research recommends nurses play a key role in ... patients. A diagnosis of lung cancer the leading ... with it high levels of stress and raises existential issues ...
Cached Medicine News:Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 3Health News:Kasich, doctors highlight the future of OARnet -- Ohio's Academic Research Network 2Health News:Kasich, doctors highlight the future of OARnet -- Ohio's Academic Research Network 3Health News:Sleeping Pills Linked to Raised Risk of Death, Cancer: Study 2Health News:Sleeping Pills Linked to Raised Risk of Death, Cancer: Study 3Health News:Study compares traits of autism, schizophrenia 2Health News:Cold air chills heart's oxygen supply 2Health News:Nurses key in helping new cancer patients overcome fears 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: